CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Pegylated interferon-alfa–2a plus adefovir combination therapy is superior to pegylated interferon-alfa–2a alone or adefovir monotherapy in reducing HBsAg levels in HDV-coinfected patients with low HBV viremia
DOI 10.1055/s-2007-967886
Bibliografische Angaben
Nachweis in CareLit
Autor:innenH Wedemeyer, C Yurdaydin, K Zachou, A Erhardt, Y Cakaloglu, H Degertekin, S Gurel, S Zeuzem, G Dalekos, T Bock, HP Dienes, MP Manns
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2007
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Serum HBsAg levels are considered as a surrogate marker for intrahepatic HBV-cccDNA levels and have been shown to be reduced by adefovir therapy in HBV-monoinfected patients. The hepatitis D virus uses the HBsAg for virion formation. Thus, the best treatment option for HDV infection would be clearance of HBsAg. Methods: We investigated HBsAg levels in 90 patients with HBV-HDV coinfection being treated…
Zitieren
Zitierempfehlung
H Wedemeyer, C Yurdaydin, K Zachou, A Erhardt, Y Cakaloglu, H Degertekin, S Gurel, S Zeuzem, G Dalekos, T Bock, HP Dienes, MP Manns (2007) Pegylated interferon-alfa–2a plus adefovir combination therapy is superior to pegylated interferon-alfa–2a alone or adefovir monotherapy in reducing HBsAg levels in HDV-coinfected patients with low HBV viremia. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-2007-967886
Mit CareLit weiterarbeiten